Lino Biotech
Latest round
- Seed
Last raised
- Nov 2020
Total raised
- Undisclosed
Investors
- 2
About Lino Biotech
Lino Biotech AG, founded in 2019, operates from Zurich, Switzerland, focusing on innovative technologies for biological interactions. The company has completed 2 deals, with its most recent deal occurring on March 22, 2023, when it was acquired by Miltenyi Biotec from High-Tech Gründerfonds and Roche Venture Fund.Lino Biotech AG specializes in advanced measurement technologies for biological interactions, with a focus on their flagship product, the MACS® Matchmaker, which utilizes focal Molography. This innovative technology enables label-free characterization of molecular dynamics in real biological systems, allowing researchers to observe and quantify biological processes without interference from labels or pre-purification steps. The company’s product offerings primarily target R&D labs in the biotech and pharmaceutical industries, facilitating applications such as antibody development and protein-protein interaction studies. The MACS® Matchmaker is designed to handle complex samples, providing high sensitivity measurements of small proteins and peptides, and can characterize multiple interactions simultaneously, significantly streamlining the experimental process.Lino Biotech AG generates revenue through the sale of its advanced instruments, sensor chips, and associated kits, focusing on B2B transactions with research institutions and biotech companies. The company’s revenue model is centered on direct sales of its products, including bulk purchasing options or subscription-based access for ongoing support and maintenance services. The MACS® Matchmaker and its related products are essential for clients involved in high-throughput research and development, facilitating efficient workflows in biologically relevant conditions.Following its acquisition on March 22, 2023, by Miltenyi Biotec, Lino Biotech AG intends to expand its product line, focusing on new measurement technologies designed for specific applications in the biotech sector. The company plans to broaden its market presence in North America and Asia by the end of 2024, leveraging synergies from the acquisition to enhance its distribution capabilities.
Who invested in Lino Biotech
2 investors across 1 round
See all investors in Lino Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Nov 17, 2020
Amount
Undisclosed
Investors
Questions about Lino Biotech
Who invested in Lino Biotech?
Lino Biotech has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lino Biotech raised?
Lino Biotech has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Lino Biotech last raise money?
Lino Biotech's most recent round on record is a Seed, in Nov 2020.
What does Lino Biotech do?
Lino Biotech AG, founded in 2019, operates from Zurich, Switzerland, focusing on innovative technologies for biological interactions.
Where is Lino Biotech headquartered?
Lino Biotech is headquartered in Zurich, Switzerland.
Which VCs invest in companies like Lino Biotech?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Lino Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Lino Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.